Soluble CD40 Ligand is associated with angiographic severity of coronary artery disease in patients with acute coronary syndrome

Chinese Medical Journal

Volumn 127, Issue 12, 2014, Pages 2218-2221

  Zhao, Wei ^a   Zhang, Fan ^a   Li, Zi Jian ^a   Yu, Hai Yi ^a   Li, Zong Shi ^a   Gao, Wei ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Acute coronary syndrome; Atherosclerosis; Coronary angiography; Coronary artery disease; Soluble CD40 ligand

Indexed keywords

ANTITHROMBOCYTIC AGENT; CD40 LIGAND; CREATINE KINASE MB; SOLUBLE CD40 LIGAND; TROPONIN T; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHEMICAL ANALYSIS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENSINI SCORE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; UNSTABLE ANGINA PECTORIS; BLOOD; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX;

ACUTE CORONARY SYNDROME; AGED; CD40 LIGAND; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84902467008     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20133159     Document Type: Article

References (24)

1. Schonbeck U. Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-1103.
2. Cipollone F, Chiarelli F, Davi G, Ferri C, Desideri G, Fazia M, et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005; 48: 1216-1224.
3. Garlichs CD, John S, Schmeisser A, Eskaf S, Stumpf C, Karl M, et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001; 104: 2395-2400.
4. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-620.
5. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111.
6. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049-1052.
7. Setianto B Y, Hartopo AB, Achadiono DN, Gharini PP. Association between levels of circulating soluble CD40 ligand on admission and in-hospital events among acute coronary syndrome patients. Acta Med Indones 2011; 43: 82-87.
8. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by co-expressed CD40. Blood 2001; 98: 1047-1054.
9. Lee Y, Lee WH, Lee SC, Ahn KJ, Choi YH, Park SW, et al. CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology 1999; 92: 11-16.
10. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macro-phage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96: 369-396.
11. Urbich C, Mallat Z, Tedgui A, Clauss M, Zeiher AM, Dimmeler S. Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest 2001; 108: 1451-1458.
12. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking infammation with atherothrombosis. J Am Coll Cardiol 2009; 54: 669-677.
13. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
14. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
15. Zakynthinos E, Pappa N. Infammatory biomarkers in coronary artery disease. J Cardiol 2009; 53: 317-333.
16. Graf D, Müller S, Korthauer U, Van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eurn J Immunol 1995; 25: 1749-1754.
17. Desideri G, Ferri C. Effects of obesity and weight loss on soluble CD40L levels. JAMA 2003; 289: 1781-1782.
18. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-2268.
19. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003; 108: 2776-2782.
20. Chai H, Aghaie K, Zhou W. Soluble CD40 ligand induces human coronary artery smooth muscle cells proliferation and migration. Surgery 2009; 146: 5-11.
21. Ferroni P, Guadagni F. Soluble CD40L and its role in essential hypertension: diagnostic and therapeutic implications. Cardiovasc Hematol Disord Drug Targets 2008; 8: 194-202.
22. Penno G, Pucci L, Dell'Omo G, Lucchesi D, Miccoli R, Del Prato S, et al. Soluble CD40 ligand levels in essential hypertensive men: evidence of a possible role of insulin resistance. Am J Hypertens 2009; 22: 1007-1013.
23. Fouad HH, Al-Dera H, Bakhoum SW, Rashed LA, Sayed RH, Rateb MA, et al. Levels of sCD40 ligand in chronic and acute coronary syndromes and its relation to angiographic extent of coronary arterial narrowing. Angiology 2010; 61: 567-573.
24. Griva M, Naplava R, Spendlikova M, Jarkovsky J, Hlinomaz O, Cihalik C. Potential role of selected biomarkers for predicting the presence and extent of coronary artery disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154: 219-225.